LNK in Polycystic Ovary Syndrome With Insulin Resistance

Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05146063
Collaborator
(none)
80
1
25.8
3.1

Study Details

Study Description

Brief Summary

Insulin resistance (IR) is an important pathological feature of polycystic ovary syndrome (PCOS), with an incidence rate of up to 85%, which seriously affects the patient's fertility, quality of life, and offspring health, but the mechanism is unknown. The adaptor protein LNK is closely related to metabolic diseases. Our exome sequencing has found that the mutation rate of LNK gene in patients with PCOS and IR is high. Studies have found that LNK can affect adipose inflammation and impair glucose tolerance. Whether LNK is related to fat metabolism is worth further study. Our previous research found that: LNK expression was significantly increased in adipose tissue of patients with PCOS and IR. Knockout of LNK in PCOS IR model mice can reduce serum triglycerides, free fatty acids, high-sensitivity C-reactive protein levels and reduce fatty liver occurrence, which indicates that LNK has a mitigating effect on IR. Mechanism studies have shown that LNK knockout can upregulate the glucose transporter Glut4, also LNK and insulin receptor substrate IRS-1 can form protein complexes. Based on the above research basis, we propose the following scientific hypothesis: LNK in adipose tissue can regulate insulin signaling pathway by binding to IRS-1, downregulate Glut4, and participate in PCOS IR occurrence. This project intends to clarify the specific mechanism by which LNK regulates glucose transport and participate in IR in combination with clinical specimens, animal models and cell experiments, and provide scientific basis for LNK as a potential therapeutic target for PCOS IR.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Take the patient's subcutaneous fat tissue to detect the expression of LNK

Study Design

Study Type:
Observational
Anticipated Enrollment :
80 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
LNK Participates in Insulin Resistance in Polycystic Ovary Syndrome by Regulating Adipose Glucose Transport
Actual Study Start Date :
Nov 5, 2021
Anticipated Primary Completion Date :
Dec 31, 2022
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Polycystic ovary syndrome patients with insulin resistance

Diagnostic Test: Take the patient's subcutaneous fat tissue to detect the expression of LNK
Take the patient's subcutaneous fat tissue to detect the mRNA and protein expression levels of LNK by RT-qPCR and western blot.

Polycystic ovary syndrome patients without insulin resistance

Diagnostic Test: Take the patient's subcutaneous fat tissue to detect the expression of LNK
Take the patient's subcutaneous fat tissue to detect the mRNA and protein expression levels of LNK by RT-qPCR and western blot.

Outcome Measures

Primary Outcome Measures

  1. mRNA expression levels of LNK [2 years]

    The expression level of LNK mRNA in the subcutaneous adipose tissue of the PCOS patients

  2. protein expression levels of LNK [2 years]

    The expression level of LNK protein in the subcutaneous adipose tissue of the PCOS patients

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 40 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with polycystic ovary syndrome who meet the 2003 Rotterdam criteria
Exclusion Criteria:
  • Do not meet the diagnostic criteria for polycystic ovary syndrome

Contacts and Locations

Locations

Site City State Country Postal Code
1 Sun Yat-sen Memorial Hospital, Sun Yat-sen University Guangzhou Guangdong China 510120

Sponsors and Collaborators

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Investigators

  • Study Director: Yi Zhang, Sun Yat-sen Memorial Hospital, Sun Yat-sen Univers

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
ClinicalTrials.gov Identifier:
NCT05146063
Other Study ID Numbers:
  • SYSEC-KY-KS-2021-187
First Posted:
Dec 6, 2021
Last Update Posted:
Dec 6, 2021
Last Verified:
Nov 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 6, 2021